From ICU to Battlefield: Vasomune's Dual-Use Strategy for Vascular Leak

TORONTO – October 05, 2026 – In the complex machinery of human biology, the breakdown of a single microscopic barrier can trigger a catastrophic systemic failure. Endotheliopathy—the pathological dysfunction of the endothelial cells lining our blood vessels—allows fluid and vital proteins to rapidly escape circulation and flood surrounding tissues. This vascular leak is the silent, underlying killer in acute respiratory distress syndrome (ARDS), severe burn trauma, and hemorrhagic shock. For decades, the standard of care has been largely supportive, relying on ventilators and fluid management while waiting for the body to heal itself.

Now, a Toronto-based clinical-stage biopharmaceutical company is attempting to change that paradigm, and they are expanding their operational canvas to do so. Vasomune Therapeutics, Inc. announced today that it has secured advisory services and up to C$280,347 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). While the dollar amount may seem modest in the capital-intensive world of biotech, the strategic implications of this specific grant are profound. The funding is earmarked not for early discovery, but for a critical logistical pivot: developing a subcutaneous formulation of the company’s lead investigational medicine, Pegevongitide (AV-001).

By transitioning this therapy from an intravenous (IV) hospital drip to a field-ready subcutaneous injection, Vasomune is effectively attempting to move critical care out of the intensive care unit and onto the battlefield, the ambulance, and the disaster zone.

From the ICU to the Battlefield

In both civilian trauma and military combat, medical professionals operate under the tyranny of the "golden hour"—the critical window immediately following a traumatic injury where rapid medical intervention yields the highest survival rates. In the austere environments of a combat zone or a mass casualty event, establishing an intravenous line is a perilous, time-consuming, and sometimes impossible task. A therapy that requires an IV pump is inherently limited to controlled clinical settings.

“We are grateful to NRC IRAP for its support in the development of Pegevongitide, having previously contributed to our Phase 1 development program,” said Dr. Brian Jahns, Chief Executive Officer of Vasomune, in the company's press release. “Vascular leak is a common theme that links many combat-relevant injuries and critical illnesses, and this support will help us advance a therapeutic that treats vascular leak directly, regardless of the underlying cause.”

The push for a subcutaneous formulation is a direct response to the procurement interests of defense and public health authorities. Vasomune has been actively aligning its clinical development with the strategic needs of the military. The company is backed by the United States Department of Defense Congressionally Directed Medical Research Programs (CDMRP) and recently presented its findings at the 2026 Military Health System Research Symposium. Furthermore, Dr. Jahns presented AV-001’s therapeutic capabilities at the NATO NSPA CBRN (Chemical, Biological, Radiological, and Nuclear) Conference this past July.

The military's interest is clear. Hemorrhagic shock remains a leading cause of preventable death on the battlefield. When a soldier suffers severe trauma, vascular leak accelerates the loss of blood volume, leading to rapid organ failure. A subcutaneous shot that could immediately activate the Tie2 receptor to stabilize the vascular endothelium would serve as a revolutionary frontline countermeasure, buying precious time for medical evacuation.

Targeting Endotheliopathy: A New Mechanistic Frontier

The science underpinning AV-001 represents a significant departure from traditional trauma and respiratory care. Discovered at the Sunnybrook Research Institute in Toronto, Pegevongitide is a first-in-class, fully synthetic PEGylated peptide. It functions as an Angiopoietin-1 (Angpt-1) mimetic, meaning it is specifically designed to activate the Tie2 tyrosine kinase receptor, which is highly expressed on the surface of endothelial cells.

When activated, the Tie2 receptor fortifies endothelial cell junctions, promoting cell survival and actively blocking the leakage of fluid into the lungs and other tissues. This mechanism addresses the root cause of edema and organ failure rather than merely managing the symptoms. The clinical trajectory of AV-001 has been accelerating rapidly. Just days ago, on September 28, 2026, Vasomune completed patient enrollment for its Phase 2a clinical study (AV001-004) evaluating the drug in patients hospitalized with pneumonia requiring supplemental oxygen—a precursor to ARDS.

The broader regulatory landscape is also taking notice. In May 2024, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to AV-001 for the prevention or treatment of moderate-to-severe ARDS. More recently, in March 2026, the FDA cleared an Investigational New Drug (IND) application allowing Vasomune to initiate a clinical program for AV-001 in the acute resuscitation of severely burned patients. Severe burns trigger massive fluid shifts and systemic shock due to extreme vascular leak; stabilizing the endothelium in these patients could drastically reduce mortality and long-term morbidity.

Vasomune is not navigating this complex clinical pathway alone. The company is developing Pegevongitide under a co-development agreement with AnGes, Inc. (TYO: 4563), a Tokyo-listed biopharmaceutical company specializing in gene-based medicines. This international partnership highlights the global commercial potential of a viable vascular leak therapy, with AnGes likely positioning to capture the Asian markets while Vasomune drives North American development.

Building Sovereign Biotech Through Non-Dilutive Capital

Beyond the clinical and military implications, Vasomune’s latest funding injection illuminates the strategic role of government programs in fostering domestic innovation. The C$280,347 grant from NRC IRAP is non-dilutive, meaning Vasomune’s founders and early investors do not have to surrender equity in exchange for the capital.

"NRC IRAP has played an important role in advancing our development efforts. Programs like NRC IRAP are essential to strengthening Canada's life sciences ecosystem and fostering innovation," noted Ms. Gosia Hodgson, Chief Financial Officer at Vasomune.

This is not the first time the Canadian government has stepped in to de-risk Vasomune’s pipeline. In November 2021, NRC IRAP provided up to $2.8 million to support the company’s Phase 1 development efforts when AV-001 was being aggressively evaluated as a COVID-19 therapeutic. By providing sustained, targeted financial support at critical formulation and trial junctures, NRC IRAP plays a vital role in keeping high-value intellectual property within Canada's borders.

Too often, promising academic spinouts—like Vasomune’s emergence from Sunnybrook—are forced to license away their most valuable assets prematurely due to the sheer cost of drug formulation and clinical testing. Non-dilutive funding bridges the "valley of death" in biotech development, allowing domestic companies to mature their assets, increase their valuation, and negotiate from a position of strength when engaging with international partners like AnGes or seeking venture capital.

The Intersection of Defense and Public Health

As we look at the macroeconomic forces shaping the biopharmaceutical industry in 2026, the concept of "dual-use" technology has never been more relevant. The same physiological mechanisms that cause a civilian to succumb to viral pneumonia-induced ARDS are responsible for the rapid deterioration of a soldier suffering from hemorrhagic shock or severe burns.

By utilizing government grants to pivot AV-001 toward a subcutaneous delivery method, Vasomune Therapeutics is effectively bridging the gap between national defense procurement and global public health. A therapy that is durable, easy to administer, and capable of halting the systemic cascade of endotheliopathy could fundamentally alter emergency triage protocols worldwide. It is a stark reminder that in the modern era of medicine, the most revolutionary breakthroughs often occur not by discovering new diseases, but by finding entirely new ways to deliver life-saving interventions to the people who need them most, precisely when they need them.